Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent

American Journal of Cardiology

Volumn 107, Issue 11, 2011, Pages 1571-1574

  Azar, Mireille ^a   Valentin, Emmanuel ^b   Badaoui, Georges ^a   Kassab, Roland ^a   Sarkis, Antoine ^a   Azar, Rabih R ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b Aterovax   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SECRETORY PHOSPHOLIPASE A2; SIMVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE CORONARY ARTERY DISEASE; STROKE; TREATMENT DURATION;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; PYRROLES; TREATMENT OUTCOME;

EID: 79956062292     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.01.038     Document Type: Article

References (14)

1. Z. Mallat, T. Simon, J. Benessiano, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N.J. Wareham, R. Luben, K.T. Khaw, A. Tedgui, and S.M. Boekholdt Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study Arterioscler Thromb Vasc Biol 27 2007 1177 1183 (Pubitemid 46641976)
2. Z. Mallat, G. Steg, J. Benessiano, M.L. Tanguy, K.A. Fox, J.P. Collet, O.H. Dabbous, P. Henry, K.F. Carruthers, A. Dauphin, C.S. Arguelles, J. Masliah, B. Hugel, G. Montalescot, J.M. Freyssinet, B. Asselain, and A. Tedgui Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes J Am Coll Cardiol 46 2005 1249 1257 (Pubitemid 41615545)
3. G. Lambeau, and M.H. Gelb Biochemistry and physiology of mammalian secreted phospholipases A2 Annu Rev Biochem 77 2008 495 520
4. C. Flood, M. Gustafsson, R.E. Pitas, L. Arnaboldi, R.L. Walzem, and J. Boren Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100 Arterioscler Thromb Vasc Biol 24 2004 564 570 (Pubitemid 38326154)
5. Y. Kleinman, E.S. Krul, M. Burnes, W. Aronson, B. Pfleger, and G. Schonfeld Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells J Lipid Res 29 1988 729 743
6. C.R. Wooton-Kee, B.B. Boyanovsky, M.S. Nasser, W.S. de Villiers, and N.R. Webb Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation Arterioscler Thromb Vasc Biol 24 2004 762 767 (Pubitemid 38451617)
7. J.K. Hakala, K. Oorni, M.O. Pentikainen, E. Hurt-Camejo, and P.T. Kovanen Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans Arterioscler Thromb Vasc Biol 21 2001 1053 1058 (Pubitemid 34168668)
8. Z. Shaposhnik, X. Wang, J. Trias, H. Fraser, and A.J. Lusis The synergistic inhibition of atherogenesis in ApoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) J Lipid Res 50 2009 623 629
9. H. Fraser, C. Hislop, R.M. Christie, H.L. Rick, C.A. Reidy, M.L. Chouinard, P.L. Eacho, K.E. Gould, and J. Trias Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice J Cardiovasc Pharmacol 53 2009 60 65
10. R.S. Rosenson, C. Hislop, D. McConnell, M. Elliott, Y. Stasiv, N. Wang, D.D. Waters PLASMA Investigators Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 2009 649 658
11. J.J.P. Kastelein, F. Akdim, E.S.G. Stroes, A.H. Zwinderman, M.L. Bots, A.F.H. Stalenhoef, F.L.J. Visseren, E.J.G. Sijbrands, M.D. Trip, E.A. Stein, D. Gaudet, R. Duivenvoorden, E.P. Veltri, A.D. Marais, E. de Groot ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
12. J.L. Fleg, M. Mete, B.V. Howard, J.G. Umans, M.J. Roman, R.E. Ratner, A. Silverman, J.M. Galloway, J.A. Henderson, M.R. Weir, C. Wilson, M. Stylianou, and W.J. Howard Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial J Am Coll Cardiol 52 2008 2198 2205
13. S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A.M. Zeiher Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patient with CAD: clinical evidence for "pleiotropic" functions of statin therapy Eur Heart J 27 2006 1182 1190
14. M. Settergren, F. Bhm, L. Rydn, and J. Pernow Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease Eur Heart J 29 2008 1753 1760 (Pubitemid 352019812)